A Changing Of The Guard At Merck R&D As Perlmutter Succeeds Kim
This article was originally published in The Pink Sheet Daily
Executive Summary
Amid growing concern over the quality of Merck’s late-stage pipeline, CEO Frazier made a decisive move to change the R&D leadership. Former Amgen R&D head Perlmutter will succeed Merck Research Laboratories President Kim in April.
You may also be interested in...
On Amgen’s Agenda: Bring Biologics To Primary Care
The big biotech is investing heavily in two late-stage drugs – one for high cholesterol and the other for osteoporosis – that will test its ability to expand its specialty marketing savvy into primary care markets. Denosumab, launched in 2010 for osteoporosis under the brand name Prolia, was a first step, but investors see bigger opportunities ahead.
Merck’s CV Pipeline: A Shrinking But Strident Commitment
Merck insists it is committed to its cardiovascular franchise, but the company has had to halt the development of several CV assets and has been plagued by poor trial results for others.
Merck CEO To Street: Watch For Short-term Adaptability, Long-Term Innovation
Newly named chairman, Merck’s CEO Ken Frazier, cites several – smallish – launches, flexibility, especially in the face of setbacks, and business development, and ongoing focus on innovation as priorities in 2012 that will lead to long-term sustainability.